BioSpace News Archive

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the March 9th & 10th H.C. Wainwright Global Life Sciences Virtual Conference.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference.

“We are delighted to collaborate with Lonza recognizing their team of experts who will lead the process development and GMP manufacture of Ixovex-1, a highly potent next-generation, tumor-selective oncolytic virus that can be used in a wide variety of solid tumors”.

Johnson // Becker, PLLC is a nationwide plaintiff’s law firm with experience representing injured men and women in lawsuits against pharmaceutical and medical device companies.

Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral, once-daily fatty acid synthase inhibitor ASC40 that is being evaluated as a potential treatment for nonalcoholic steatohepatitis.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the successful completion and settlement of its US$110 million private placement led by a strategic US investor group, that was announced on Tuesday, March 2, 2021.

On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as “Winhealth Pharma”) signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as “Merz”).

CTI BioPharma Corp. announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of March 8, 2021, as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.